EUROPE RESEARCH ROUNDUP-AstraZeneca, Beazley, Puma Aug 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Beazley and Puma on Monday. HIGHLIGHTS * AstraZeneca AZN.L : TD Cowen raises target price to 14,860p from 13,945p * Beazley BEZG.L : Jefferies raises target price to 1,020p from 975p * Puma SE PUMG.DE : Baader Helvea raises to buy from add * Quilter Plc QLT.L : Berenberg raises target price to 135p from 105p * WPP

UPDATE 1-British mid-cap stocks close at over two-year high on earnings optimism For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. FTSE 100 up 1.2%, FTSE 250 gains 2.3% US PCE in line with estimates Focus on Fed, BoE decisions next week Updated at 1620 GMT July 26 (Reuters) - British mid-cap stocks rallied to their strongest finish in more than two years on Friday, helped by a slew of upbeat company earnings reports and a rebound on Wall

BUZZ-UK's Babcock gains as co reaffirms FY25 forecast ** Shares in British defense engineering company Babcock International BAB.L up 2.7% to 501.2 pence ** Co says its expectations for FY25 remain unchanged with a target to deliver mid-single digit average annual revenue growth nFWN3JI0P0 ** Posts underlying operating profit of 237.8 mln pounds ($

EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever July 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Greencore, UCB, and Unilever, on Friday. HIGHLIGHTS * Greencore GNC.L : HSBC raises target price to 190p from 160p * Lonza Group AG LONN.S : JP Morgan raises target price to CHF 645 from CHF 600 * Sartorius Stedim Biotech STDM.PA : HSBC cuts target price to EUR 310 from EUR 360 * UCB SA UCB.BR : TD Cowen raises target price to E

BRIEF-Babcock International Maintains FY25 Expectations July 26 (Reuters) - Babcock International Group PLC BAB.L : STRONG PROGRESS TOWARDS OUR MEDIUM-TERM GUIDANCE EXPECTATIONS FOR FY25 REMAIN UNCHANGED C.70% OF FY25 EXPECTED REVENUE UNDER CONTRACT AT 1 APRIL 2024 Source text for Eikon: ID:nRSZ9468Xa Further company coverage: BAB.L